Medical research in Africa: From pharmacopoeia to industrial sovereignty

Every health industry begins with research. Without basic research, there are no patents. Without patents, there is no sustainable added value.

The health value chain begins with research and development, a capital-intensive and strategic segment.

Underutilised scientific potential

Africa has considerable pharmacopoeial wealth. Billions of people worldwide still use traditional medicines, and the WHO has launched a dedicated traditional medicine strategy for the 2025–2034 period.

Yet the scientific and industrial valorisation of this knowledge remains limited on the continent.

From knowledge to patent

Turning an active ingredient into a medicine requires:

• Stable funding
• Rigorous clinical trials
• Public-private partnerships
• Intellectual property protection

Countries able to structure this chain capture the highest value in the pharmaceutical industry. Medical research in Africa should not be seen as a cost, but as a strategic investment.

A technological sovereignty issue

Globally, patents determine access to markets and financing. Failing to invest in research means depending on foreign innovation.

What we analyse in the Special Report

The Special Health Report explores:

• The full chain from R&D to marketing authorisation
• The role of universities
• The opportunities linked to African pharmacopoeias
• Long-term investment levers

>> Access the full analysis in K-World Magazine No. 17 (French)